Actively Recruiting
Immunotherapy With Adaptive Pulse Radiotherapy in Solid Tumors
Led by Samsung Medical Center · Updated on 2026-02-02
35
Participants Needed
1
Research Sites
313 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to find out whether Adaptive Pulse Radiotherapy (Pulse RT) combined with immune checkpoint inhibitors (ICIs) helps treat advanced solid tumors. It will also check how safe this combined treatment is and how it affects the immune system and quality of life. The main questions the study will try to answer are: Does adding Pulse RT to ICIs improve tumor response and survival? What side effects occur when participants receive Pulse RT with ICIs? How does the treatment change immune-related blood and tissue markers? Does the treatment affect participants' quality of life? Researchers will compare this new approach to usual ICI treatment to see whether Pulse RT makes a difference. Participants will: Continue to receive their standard ICI treatment. Receive 2-3 sessions of high-dose Pulse RT (8-10 Gy each) given about every 3 weeks. Have the treatment volume adjusted based on how their tumors respond. Visit the clinic regularly for check-ups, imaging, blood tests, and quality-of-life questionnaires.
CONDITIONS
Official Title
Immunotherapy With Adaptive Pulse Radiotherapy in Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Histologically confirmed solid tumor (radiologic diagnosis allowed for hepatocellular carcinoma)
- Currently receiving or planned to receive immune checkpoint inhibitor therapy
- At least one lesion suitable for radiotherapy and measurable by RECIST version 1.1
- Ability and willingness to provide written informed consent
You will not qualify if you...
- Pregnant or breastfeeding women
- Presence of brain metastasis or leptomeningeal metastasis
- Prior radiotherapy to the planned treatment site
- Significant comorbid conditions interfering with participation or treatment (e.g., uncontrolled infection, heart failure, arrhythmia, psychiatric disorder)
- Inability or unwillingness to comply with study procedures
- Considered inappropriate for participation by the principal investigator or treating physician
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Samsung medical center
Seoul, South Korea, 06351
Actively Recruiting
Research Team
N
Nalee Kim, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here